Novo Nordisk

6-K 1 f6k_111125.htm FORM 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____

FORM 6-K

____

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

November 11, 2025

____

NOVO NORDISK A/S

(Exact name of Registrant as specified in its charter)

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

____

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F ☐

Field: Page; Sequence: 1

Field: /Page

Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 11 November 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.

Field: Page; Sequence: 2

Field: /Page

Page 2 of 4

| 1 — a) | Details
of the person discharging managerial responsibilities/person closely associated — Name of the Board member/Executive/Associated
Person | David
Moore | |
| --- | --- | --- | --- |
| 2 | Reason for the notification | | |
| a) | Position/status | Executive
Vice President, US Operations | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | | |
| a) | Name | Novo
Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | | |
| a) | Description of the financial instrument, type of instrument, | Shares | |
| | Identification
code | Novo Nordisk
B DK0062498333 | |
| b) | Nature
of the transaction | Other
transaction (acquisition of shares in accordance with the recruitment package) | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | DKK 0.00 | 18,634 |
| d) | Aggregated information · Aggregated volume · Price | 18,634 shares DKK 0.00 | |
| e) | Date
of the transaction | 2025-11- 10 | |
| f) | Place
of the transaction | Outside
a trading venue | |

Field: Page; Sequence: 3

Field: /Page

Page 3 of 4

| 1 — a) | Details
of the person discharging managerial responsibilities/person closely associated — Name of the Board member/Executive/Associated
Person | David
Moore | |
| --- | --- | --- | --- |
| 2 | Reason for the notification | | |
| a) | Position/status | Executive
Vice President, US Operations | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | | |
| a) | Name | Novo
Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | | |
| a) | Description of the financial instrument, type of instrument, | Shares | |
| | Identification
code | Novo Nordisk
B DK0062498333 | |
| b) | Nature
of the transaction | Sale of shares | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | DKK 297.95 | 8,160 |
| d) | Aggregated information · Aggregated volume · Price | 8,160 shares DKK 2,431,301.74 | |
| e) | Date
of the transaction | 2025-11- 10 | |
| f) | Place
of the transaction | Nasdaq Copenhagen | |

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Field: Page; Sequence: 4; Options: NewSection

Field: /Page

Page 4 of 4

Contacts for further information

Media :
Ambre James- Brown	Liz Skrbkova (US)
+45 3079 9289	+1 609 917 0632
[email protected]	[email protected]
Investors:
Jacob Martin Wiborg Rode	Sina Meyer
+45 3075 5956	+45 3079 6656
[email protected]	[email protected]
Christoffer Sho Togo Tullin	Alex Bruce
+45 3079 1471	+45 3444 2613
[email protected]	[email protected]
Frederik Taylor Pitter
+1 609 613 0568
[email protected]

Novo Nordisk A/S Investor Relations
Company announcement No 33 / 2025

Field: Page; Sequence: 5

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: November 11, 2025 NOVO NORDISK A/S Maziar Mike Doustdar Chief Executive Officer

Field: Rule-Page

Field: /Rule-Page

AI Terminal

More from Novo Nordisk

Talk to a Data Expert